Table 1 Patient characteristics

From: Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer

No. of patients

22

Median age, years (range)

57 (34–70)

Sex (M/F)

15/7

Primary tumour site

 

 Colon

5

 Rectum

11

 Rectosigmoid

6

Karnofsky performance status

 

 100

2

 90

16

 80

3

 70

1

 <70

0

No. of sites of metastatic disease

 

 1

10

 >1

12

Sites of metastatic disease

 

 Liver

7

Lung

2

 Liver and lung

8

 LN

1

 Liver and LN

2

 Lung and LN

2

  1. LN=lymph node.